Eli Lilly (NYSE:LLY) gave its presentation at the JPMorgan conference on health care last week, and in this video, Motley Fool health care bureau chief Brenton Flynn gives us three important takeaways for Eli Lilly investors. He tells us to look out for a huge amount of data from the company on testing of some of the drugs in its pipeline in both the diabetes and oncology spaces, and discusses the possibility that the company may seek approval outside of the U.S. for its Alzheimer's candidate drug. He goes on to highlight the company's strong balance sheet and the possibility of a merger or acquisition somewhere down the road.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.